{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T07:30:01Z","timestamp":1777879801245,"version":"3.51.4"},"reference-count":52,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/501100003710","name":"orea Health Industry Development Institute","doi-asserted-by":"publisher","award":["HI22C0108"],"award-info":[{"award-number":["HI22C0108"]}],"id":[{"id":"10.13039\/501100003710","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Therapeutic Advances in Psychopharmacology"],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>In February 2025, the FDA ended the mandatory Risk Evaluation and Mitigation Strategy requirements for clozapine. Korea continues mandatory hematologic testing under the Clozapine Patient Monitoring System (CPMS), yet no nationwide updates have been reported since 2006.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives:<\/jats:title>\n                    <jats:p>This study aimed to provide contemporary real-world evidence on the incidence, timing, and clinical outcomes of clozapine-associated neutropenia and agranulocytosis in Korea, and to evaluate adherence to monitoring regulations, to inform potential revision of the national CPMS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design:<\/jats:title>\n                    <jats:p>A retrospective, multicenter cohort study was conducted using anonymized electronic medical records from two Korean tertiary hospitals between 2000 and 2023.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Patients with schizophrenia spectrum disorders who had newly initiated clozapine were included. Absolute neutrophil count (ANC) data were used to identify neutropenia (ANC &lt; 1500\/\u03bcL), moderate neutropenia (&lt;1000\/\u03bcL), and agranulocytosis (&lt;500\/\u03bcL). Chart review determined causality for agranulocytosis. Monitoring adherence was assessed based on the proportion of ANC tests conducted within recommended intervals.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Among 2417 newly initiated patients (from 3364 total users), neutropenia occurred in 9.7%. Of these, 47.4% occurred within 18 weeks, and none who continued treatment progressed to agranulocytosis. Patients with neutropenia had lower baseline ANC than those without. Moderate neutropenia occurred in 1.7% and showed similar clinical patterns, most events being transient. Ten cases of agranulocytosis were identified, of which four (0.17%) were clozapine-related. All appeared abruptly within 5 weeks of initiation without preceding neutropenia or low baseline ANC, and recovered after discontinuation. Monitoring adherence was suboptimal: during the first 18 weeks, adherence to \u2a7d10-day interval was 73.7%, while 8.7% patients had no ANC tests; adherence after 1 year fell below 50%.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Neutropenia is relatively common but usually low-risk, whereas clozapine-induced agranulocytosis is rare, abrupt, and confined to the early period. These findings suggest reconsideration of current hematological monitoring regulations regarding clozapine.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/20451253261440341","type":"journal-article","created":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T05:55:48Z","timestamp":1776059748000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Clozapine-related neutropenia and agranulocytosis in Korea: 2025 update for rethinking the role of monitoring system"],"prefix":"10.1177","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7630-4033","authenticated-orcid":false,"given":"Nuree","family":"Kang","sequence":"first","affiliation":[{"name":"Department of Psychiatry, Gyeongsang National University Hospital, Jinju, Republic of Korea"},{"name":"Department of Psychiatry, Gyeongsang National University College of Medicine, Jinju, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ji Seon","family":"Jang","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Kyungpook National University Hospital, Daegu, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sung Woo","family":"Joo","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-8283-5780","authenticated-orcid":false,"given":"Jeong Hoon","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Seoul National University Hospital, Seoul, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jae Hoon","family":"Jeong","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Nowon Eulji Medical Center, Eulji University, Seoul, Republic of Korea"},{"name":"Department of Psychiatry, Eulji University School of Medicine, Daejeon, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minah","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Seoul National University Hospital, Seoul, Republic of Korea"},{"name":"Department of Psychiatry, Seoul National University College of Medicine, Seoul, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong Min","family":"Ahn","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Seoul National University Hospital, Seoul, Republic of Korea"},{"name":"Department of Psychiatry, Seoul National University College of Medicine, Seoul, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun Soo","family":"Kwon","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Hanyang University Hospital, Seoul, Republic of Korea"},{"name":"Department of Psychiatry, Hanyang University College of Medicine, Seoul, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong Sik","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Nowon Eulji Medical Center, Eulji University, Seoul, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jung Sun","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-Ro 43-Gil, SongPa-Gu, Seoul 05505, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7078-2835","authenticated-orcid":false,"given":"Se Hyun","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Seoul National University Hospital, 101 Daehak-ro, Jongro-gu, Seoul 03080, Republic of Korea"},{"name":"Department of Psychiatry, Seoul National University College of Medicine, Seoul, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2026,4,12]]},"reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)60733-3"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1111\/acps.13111"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2021.07.040"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)60742-X"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00606409"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1988.01800330013001"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2024.04.012"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0000000000000478"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.22m14588"},{"key":"e_1_3_4_11_2","unstructured":"U.S. Food and Drug Administration. Information for patients and providers: Clozapine https:\/\/www.fda.gov\/drugs\/postmarket-drug-safety-information-patients-and-providers\/information-clozapine (2025 accessed 1 May 2025)."},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1176\/appi.pn.2025.04.4.22"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1192\/j.eurpsy.2024.1816"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0000000000001765"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-020-04215-y"},{"key":"e_1_3_4_16_2","first-page":"74","article-title":"Risk of clozapine-associated agranulocytosis and mandatory white blood cell monitoring: can the regulations be relaxed?","volume":"268","author":"Schulte PFJ","year":"2024","unstructured":"Schulte PFJ, Veerman SRT, Bakker B, et al. Risk of clozapine-associated agranulocytosis and mandatory white blood cell monitoring: can the regulations be relaxed? Schizophr Res 2024; 268: 74\u201381.","journal-title":"Schizophr Res"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1017\/S204579602200066X"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2023.0376"},{"key":"e_1_3_4_19_2","unstructured":"Viatris Korea. Clozaril\u00ae (clozapine) prescribing information. Republic of Korea: Viatris Korea 2025. https:\/\/www.whanin.com\/_product\/view.php?item=204"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1002\/hup.779"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2007.11.008"},{"key":"e_1_3_4_22_2","volume-title":"StatPearls","author":"Rout P","year":"2025","unstructured":"Rout P, Reynolds SB, Zito PM. Neutropenia. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing Copyright\u00a9 2025, StatPearls Publishing LLC., 2025."},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.1136\/gpsych-2022-100773"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1055\/a-1625-6388"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1751-7893.2012.00374.x"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.jcp.0000106221.36344.4d"},{"key":"e_1_3_4_27_2","volume-title":"FDA Briefing Document: Risk Evaluation and Mitigation Strategy (REMS) for Clozapine products. Joint meeting of the Drug Safety and Risk Management Advisory Committee and the Psychopharmacologic Drugs Advisory Committee","author":"U.S. Food and Drug Administration","year":"2024","unstructured":"U.S. Food and Drug Administration. FDA Briefing Document: Risk Evaluation and Mitigation Strategy (REMS) for Clozapine products. Joint meeting of the Drug Safety and Risk Management Advisory Committee and the Psychopharmacologic Drugs Advisory Committee. November 19, 2024. Silver Spring, MD: U.S. Food and Drug Administration."},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2215-0366(23)00343-7"},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1000360"},{"key":"e_1_3_4_30_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature15393"},{"key":"e_1_3_4_31_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12889-025-21330-5"},{"key":"e_1_3_4_32_2","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.2025.10423"},{"key":"e_1_3_4_33_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12888-016-1167-0"},{"key":"e_1_3_4_34_2","doi-asserted-by":"publisher","DOI":"10.1111\/acps.13818"},{"key":"e_1_3_4_35_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199307153290303"},{"key":"e_1_3_4_36_2","first-page":"233","article-title":"Blood dyscrasias in clozapine-treated patients in Italy","volume":"85","author":"Deliliers GL","year":"2000","unstructured":"Deliliers GL. Blood dyscrasias in clozapine-treated patients in Italy. Haematologica 2000; 85: 233\u2013237.","journal-title":"Haematologica"},{"key":"e_1_3_4_37_2","first-page":"1","article-title":"Clozapine in China","volume":"41","author":"Mao P-X","year":"2008","unstructured":"Mao P-X, Jiang F, Chen Q, et al. Clozapine in China. Pharmacopsychiatry 2008; 41: 1\u20139.","journal-title":"Pharmacopsychiatry"},{"key":"e_1_3_4_38_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-146-9-200705010-00009"},{"key":"e_1_3_4_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2215-0366(24)00097-X"},{"key":"e_1_3_4_40_2","doi-asserted-by":"publisher","DOI":"10.3390\/pharmacy12030092"},{"key":"e_1_3_4_41_2","doi-asserted-by":"publisher","DOI":"10.1192\/bjb.2024.38"},{"key":"e_1_3_4_42_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41537-022-00232-0"},{"key":"e_1_3_4_43_2","doi-asserted-by":"publisher","DOI":"10.2217\/pgs-2018-0188"},{"key":"e_1_3_4_44_2","doi-asserted-by":"publisher","DOI":"10.1111\/acps.12898"},{"key":"e_1_3_4_45_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12888-020-02592-2"},{"key":"e_1_3_4_46_2","doi-asserted-by":"publisher","DOI":"10.1021\/tx800389u"},{"key":"e_1_3_4_47_2","doi-asserted-by":"publisher","DOI":"10.2165\/00023210-199707020-00005"},{"key":"e_1_3_4_48_2","doi-asserted-by":"publisher","DOI":"10.1038\/tpj.2017.6"},{"key":"e_1_3_4_49_2","article-title":"Candidate gene analysis identifies a polymorphism in HLA-DQB1 associated with clozapine-induced agranulocytosis","volume":"71","author":"Athanasiou MC","year":"2010","unstructured":"Athanasiou MC, Dettling M, Cascorbi I, et al. Candidate gene analysis identifies a polymorphism in HLA-DQB1 associated with clozapine-induced agranulocytosis. J Clin Psychiatry 2010; 71: 2240.","journal-title":"J Clin Psychiatry"},{"key":"e_1_3_4_50_2","doi-asserted-by":"publisher","DOI":"10.1177\/02698811241262767"},{"key":"e_1_3_4_51_2","doi-asserted-by":"publisher","DOI":"10.1038\/mp.2016.66"},{"key":"e_1_3_4_52_2","doi-asserted-by":"publisher","DOI":"10.1080\/01612840.2025.2503132"},{"key":"e_1_3_4_53_2","first-page":"265","article-title":"Absolute neutrophil count and adverse drug reaction monitoring during clozapine treatment: consensus guidelines from a global Delphi panel","volume":"12","author":"Siskind D","year":"2025","unstructured":"Siskind D, Northwood K, Pillinger T, et al. Absolute neutrophil count and adverse drug reaction monitoring during clozapine treatment: consensus guidelines from a global Delphi panel. Lancet Psychiatry 2025; 12: 265\u2013276.","journal-title":"Lancet Psychiatry"}],"container-title":["Therapeutic Advances in Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/20451253261440341","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/20451253261440341","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/20451253261440341","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T23:54:05Z","timestamp":1777593245000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/20451253261440341"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":52,"alternative-id":["10.1177\/20451253261440341"],"URL":"https:\/\/doi.org\/10.1177\/20451253261440341","relation":{},"ISSN":["2045-1253","2045-1261"],"issn-type":[{"value":"2045-1253","type":"print"},{"value":"2045-1261","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4]]},"article-number":"20451253261440341"}}